Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Glucagon; related peptides
Reexamination Certificate
2007-08-21
2007-08-21
Lukton, David (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Glucagon; related peptides
C530S324000, C530S399000, C514S012200
Reexamination Certificate
active
10450124
ABSTRACT:
The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range.
REFERENCES:
patent: 5512549 (1996-04-01), Chen et al.
patent: 5977071 (1999-11-01), Galloway et al.
patent: 6458924 (2002-10-01), Knudsen et al.
patent: 6504005 (2003-01-01), Fridkin et al.
patent: 6583111 (2003-06-01), DiMarchi et al.
patent: 6747006 (2004-06-01), Efendic
patent: 6849708 (2005-02-01), Habener
patent: 6884579 (2005-04-01), Holst et al.
patent: 2003/0220274 (2003-11-01), Oh et al.
patent: 0 926 159 (1999-06-01), None
patent: 1 076 066 (2001-02-01), None
patent: WO99 43708 (1999-09-01), None
patent: WO 02 47715 (2002-06-01), None
patent: WO 02 48183 (2002-06-01), None
Schirra J Journal of Clinical Investigation 101 (7) 1421-30, 1998.
Gutniak M. K. Diabetes Care 19 (8) 843-8, 1996.
Yen T. T. (Archives Internationales de Pharmacodynamie et de Therapie 310,162-74, 1991).
Koike D (Gastroenterology 108(4), 1221-9, 1995).
Dunbar J. C. (Diabetologia 14(1), 53-58, 1978).
Schmidt P. T. (Regulatory Peptides 116 (1-3) 21-5, 2003).
Deacon, C. F., et al. “Depeptidyl Peptidase IV Resistant Analogues of Glucagon-like Peptide-1 Which Have Extended Metabolic Stability and Improved Biological Activity,” Diabetologia, Berlin, DE, vol. 41, 1998, pp. 271-278. XP002202152.
Greig, N. H., et al. “Once Daily Injection of Exendin-4 to Diabetic Mice Achieves Long-Term Beneficial Effects on Blood Glucose Concentrations,” Diabetologia, Berlin, DE, vol. 42, No. 1, Jan. 1999, pates 45-50, XP 000971927.
Knudsen, L. B., et al, “Potent Derivatives of Glucagon-Like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration,” Journal of Medicinal Chemistry, American Chemical Society. Washington, US, vol. 43, No. 9 (May 4, 2000), pp. 1664-1669, XP 002222050.
Dodd Steven Witt
Mace Kenneth Francis
Trautmann Michael Ernst
Cox Gregory A.
Eli Lilly and Company
Lukton David
Martinez Alejandro
LandOfFree
Chronic treatment regimen using glucagon-like insulinotropic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chronic treatment regimen using glucagon-like insulinotropic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chronic treatment regimen using glucagon-like insulinotropic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3866221